Stefano Pileri

Has grant

Direttore della Ematopatologia

European Institute of Oncology
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

MOLECULAR BASES OF DISEASE DISSEMINATION IN LYMPHOID MALIGNANCIES TO OPTIMIZE CURATIVE THERAPEUTIC STRATEGIES

Open Date: 2018-07-01

Close Date: 2025-06-01

Articles (12)

Purpose: A risk-adapted treatment strategy, the ISG/OS-2 trial, evaluated the use of mifamurtide in patients with P-glycoprotein (Pgp)–positive localized osteosarcoma. The primary objective was the identification of prognostic classifiers based on tumor microenvironment (TME) gene profiling in all patients and in those undergoing mifamurtide treatment. Experimental Design: RNA from pretreatment formalin-fixed, paraffin-embedded nondecalcified tissues of 62 patients was analyzed with the PanCancer Immune Profiling Panel (NanoString Technologies). Thirty-three (53%) of 62 Pgp-positive patients underwent chemotherapy + mifamurtide; 29 (47%) of 62 Pgp-negative patients received chemotherapy alone. Univariate Cox regression, ROC curve, and CIBERSORTx algorithm gene deconvolution analyses were performed. Results: A 21-gene signature able to stratify all patients into high risk (Hi-R) and low risk (Lo-R) was identified: 5-year overall survival (OS) of 47% for Hi-R and 92% for Lo-R (P = 3e−06). TME of Lo-R compared with Hi-R was significantly enriched in CD8 T cells, regulatory T cells, and NK-activated cells and diminished in CD4 T cells. The 21-gene signature was validated in two independent sets: TARGET-OS The Cancer Genome Atlas (n = 62) and GSE33382 (n = 57). For patients treated with chemotherapy + mifamurtide, 31 mifamurtide-related genes able to distinguish Hi-R and Lo-R in terms of OS (P = 1e−09) and event-free survival (P = 3e−06) were also identified. After multivariate analysis, the 21- and 31-gene mifamurtide-related signatures were independently associated with OS (P = 0.00044 and P = 0.000079, respectively). Conclusions: A validated osteosarcoma TME prognostic gene signature has been identified, regardless of mifamurtide treatment. Importantly, a mifamurtide-related signature was also developed. Tumor–immune interactions possibly implicated in disease progression and treatment response were shown.

Year:

2025

Supplementary Figure S6: Venn diagram showing the 5 genes which are shared between the 21-gene signatureidentified in 62 primary osteosarcomas (discovery set) and the 31-gene signature related to the 33 osteosarcoma patients who underwent mifamurtide treatment

Year:

2025

Cox regression output , 31 genes selected based on LogRank≤0.05 significantly associated with overall survival (OS) in 33 localized primary high-grade osteosarcoma underwent chemotherapy (CT) combined with mifamurtide treatment

Year:

2025

Purpose: A risk-adapted treatment strategy, the ISG/OS-2 trial, evaluated the use of mifamurtide in patients with P-glycoprotein (Pgp)–positive localized osteosarcoma. The primary objective was the identification of prognostic classifiers based on tumor microenvironment (TME) gene profiling in all patients and in those undergoing mifamurtide treatment. Experimental Design: RNA from pretreatment formalin-fixed, paraffin-embedded nondecalcified tissues of 62 patients was analyzed with the PanCancer Immune Profiling Panel (NanoString Technologies). Thirty-three (53%) of 62 Pgp-positive patients underwent chemotherapy + mifamurtide; 29 (47%) of 62 Pgp-negative patients received chemotherapy alone. Univariate Cox regression, ROC curve, and CIBERSORTx algorithm gene deconvolution analyses were performed. Results: A 21-gene signature able to stratify all patients into high risk (Hi-R) and low risk (Lo-R) was identified: 5-year overall survival (OS) of 47% for Hi-R and 92% for Lo-R ( P = 3e−06). TME of Lo-R compared with Hi-R was significantly enriched in CD8 T cells, regulatory T cells, and NK-activated cells and diminished in CD4 T cells. The 21-gene signature was validated in two independent sets: TARGET-OS The Cancer Genome Atlas ( n = 62) and GSE33382 ( n = 57). For patients treated with chemotherapy + mifamurtide, 31 mifamurtide-related genes able to distinguish Hi-R and Lo-R in terms of OS ( P = 1e−09) and event-free survival ( P = 3e−06) were also identified. After multivariate analysis, the 21- and 31-gene mifamurtide-related signatures were independently associated with OS ( P = 0.00044 and P = 0.000079, respectively). Conclusions: A validated osteosarcoma TME prognostic gene signature has been identified, regardless of mifamurtide treatment. Importantly, a mifamurtide-related signature was also developed. Tumor–immune interactions possibly implicated in disease progression and treatment response were shown.

Year:

2025

Supplementary Figure S2:Overall survival of 62 patients with localized osteosarcoma (A) after a median follow-up of 107.8 months (IQR:92.5–128.4). (B) Overall survival for the 62 patients considered in the present study stratified as Pgp-positive and Pgp-negative (p = 0.6990).

Year:

2025

Background: Richter syndrome (RS) represents a major unmet need in the lymphoma field, being refractory to chemoimmunotherapy and targeted agents. The BCL-2 inhibitor venetoclax in combination with dose-adjusted EPOCH-R chemoimmunotherapy showed promising efficacy in patients affected by RS. However, responses were not durable, suggesting the need for further treatment optimization. Methods: Here, we report two cases of RS achieving long-term complete remission with intensified chemoimmunotherapy (Rituximab-G-MALL B-ALL/NHL2002 regimen) plus venetoclax induction, followed by haploidentical hematopoietic stem cell transplant (allo-HSCT). Venetoclax was given continuously for 14 consecutive days after every Rituximab-G-MALL cycle in off-label use. An accelerated venetoclax rump-up schedule was used in both patients to reach the maximal dose. Maximal venetoclax dose was 300 mg and 400 mg in patient 1 and patient 2, respectively. Results: The combined treatment was well tolerated, with no major infective complications or non-hematological toxicities. In both patients, immunosuppression was discontinued within day 180 after transplant with no graft-versus-host-disease flares. Both patients are alive and in continuous complete remission after 60 and 72 months following allo-HSCT. Conclusions: This report supports the feasibility of a combination treatment with BCL-2 inhibitors and intensive chemoimmunotherapy as a bridge to allo-HSCT in RS.

Year:

2024

Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (27)

Stefan Barta

Academic Clinician Associate Professor

University of Pennsylvania

UNITED STATES
View details

Emanuela Palmerini

Professor of Medicine

University of Toronto

ITALY
View details

ALESSANDRO FRANCHI

Professor of pathology

University of Pisa

ITALY
View details

alberto righi

IRCCS Istituto Ortopedico Rizzoli

ITALY
View details

Daniel J. Powell

Associate Professor

University of Pennsylvania

UNITED STATES
View details

DAVIDE MARIA DONATI

Istituto Ortopedico Rizzoli

ITALY
View details

Thomas Tousseyn

Professor Dr. at KU Leuven

KU Leuven

BELGIUM
View details

Gerald Linette

Professor

University of Pennsylvania

UNITED STATES
View details

Mohamed Abdel-Mohsen

Associate Professor

Northwestern University

UNITED STATES
View details

Claudio Agostinelli

Associate Professor of Pathology

University of Bologna

ITALY
View details

cristina meazza

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

Giovanna Motta

Istituto Europeo di Oncologia

ITALY
View details

Stefan Dojcinov

Professor / Consultant Pathologist

Swansea Bay University Health Board

UNITED KINGDOM
View details

Alessandro Pileri

Associated Professor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

ITALY
View details

Monika Klimkowska

Karolinska University Hospital

SWEDEN
View details

John Radford

The University of Manchester

UNITED KINGDOM
View details

David Teachey

Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Antonia Rotolo

Imperial College London

UNITED KINGDOM
View details

Adam Snook

Professor

Thomas Jefferson University

UNITED STATES
View details

Stephen Schuster

Professor, Clinician-Educator

Hospital of the University of Pennsylvania

UNITED STATES
View details

Massimo Serra

Chief of the "Pharmacogenomics and Pharmacogenetics" Research Unit (Struttura Semplice)

IRCCS Istituto Ortopedico Rizzoli

ITALY
View details

Francine Foss

Yale University

UNITED STATES
View details

Marco Gambarotti

IRCCS Istituto Ortopedico Rizzoli

ITALY
View details

Elisa Carretta

IRCCS Istituto Ortopedico Rizzoli

ITALY
View details

Marco Ruella

PI

University of Pennsylvania

UNITED STATES
View details

FRANCA FAGIOLI

Professore Ordinario di Pediatria

Università degli Studi di Torino

ITALY
View details

Giorgio Frega

Istituto Ortopedico Rizzoli

ITALY
View details